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  Measurement  of  serum  creatinine  (Cr)  and  blood  urea  nitrogen  (BUN)  are  used  as 
indicators of glomerular filtration rate. The increased levels of these biomarkers are usually 
detectable at advanced stages of kidney complications. The aim of this study was to find the 
interrelationship of beta-2 microglobulin (β2M), BUN and Cr in streptozotocin (STZ)-induced 
diabetes mellitus in rabbits. Diabetes was induced by a single intraperitoneal (IP) injection of 65 
mg kg-1 of STZ in rabbits. The levels of serum insulin, glucose and three above mentioned 
biomarkers were measured one day before (day -1) and on days 1-3 after injection of STZ and 
continued weekly to the end of the experiment (12 weeks). A statistically significant increase of 
serum  β2M,  BUN,  Cr  and  glucose  levels,  and  a  significant  decrease  of  insulin  levels  were 
observed in diabetic animals. However, β2M levels increased as early as one day after STZ 
injection compared to Cr and BUN that elevated at day two, suggesting a probable diagnostic 
advantage of β2M over currently used biomarkers in diabetic related kidney complications. 
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قلا ،سوتيلم تبايد هب لاتبم ׌اه شوگرخ رد نينيتار֩ و ينيتورپ ريغ تزا ،نيلوبولگور֩يم ود اتب يمرس حوطس طابترا يبايزرا ا   نيسوتوزوتپرتسا طسوت هدش  
 هدي֩چ  
ب حوطس ه֩ دشاب ׌م اه ه׌ل֩ ׌لورمول֯ نو׌سارتل׌ف ׌با׌زرا رد ׌مهم صخاش ن׌ن׌تار֩ و نوخ ةروا ن֘ورت׌ن شجنس  اتب شقن ندوب نشور اب .دوش ׌م هد׌د اه ه׌ل֩ ׌׌اسران دراومرد لاومعم اهنآ ׌لاا
ن׌لوبول֯ور֩׌م ود   رد   ص׌خشت   دوز   ما֯نه   تلا֩شم   ،׌و׌ل֩   رد   ن׌ا   هعلاطم   ر׌داقم   ׌مرس   ن׌لوبول֯ور֩׌م ود اتب   رد   ران֩   ن ׌ ن֘ورت   قلا ׌تبا׌د ׌اه شو֯رخ رد ن׌لوسنا و ز֩ول֯ ،ن׌نتآر֩ ، نوخ ةروا ا  
 اب هدش ناز׌م هب ن׌سوتوزوتپرتسا زود ֩׌ روظنم ن׌ا ׌ارب .دش ׌ر׌֯ هزادنا ن׌سوتوزوتپرتسا   56    مر֯ول׌֩ رب مر֯ ׌ل׌م  لصاوف اب ق׌رزت زا دعب و لبق نوخ هنومن .د׌در֯ ق׌رزت اه شو֯رخ هب ندب نزو
׌نامز   42    ، 24    و 24    و تعاس  ةتفه ات لوا هتفه 24    ر֩ذلا قوف ׌׌ا׌م׌شو׌ب ׌اهصخاش و هدش ذخا  اتب راد ׌نعم ش׌ازفا ةدنهد ناشن هعلاطم ج׌اتن .د׌در֯ هس׌اقم لرتن֩ هور֯ اب و ׌ر׌֯ هزادنا اهنآ مرس رد
ن׌لوبول֯ور֩׌م ود   ،   ن ׌ ن֘ورت   ز֩ول֯ و ن׌نتآر֩ ، نوخ ةروا   ׌م ود اتب ׌مرس ناز׌م رد راد ׌نعم ش׌ازفا .دوب ملاس هور֯ اب سا׌ق رد ׌تبا׌د هور֯ رد ن׌لوسنا راد ׌نعم شها֩ و ن׌لوبول֯ور֩   رد   هس׌اقم   اب  
ن ׌ ن֘ورت   ֩׌( رتدوز ن׌نتآر֩ و نوخ ةروا   دومن زورب )زور .  
:׌ديل֩ ׌اه هژاو   ،ن׌سوتوزوتپرتسا   اتب   ود   ،ن׌لوبول֯ور֩׌م   تبا׌د   سوت׌لم  
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Introduction 
 
Diabetes  mellitus  has  been  considered  the  most 
common cause of end-stage renal disease (ESRD) in the 
United States and Europe, and up to 30% of patients with 
type I or type II diabetes develop evidence of nephron-
pathy.1  Diabetic  nephropathy, which  is  caused  by 
accumulation  of  leukocytes  in  the kidney glomeruli,  is 
characterized by nephrotic syndrome and diffuse glomerulo-
sclerosis.2 Diabetic nephropathy is diagnosed by a routine 
urinalysis and by screening for microalbuminuria.1  
Several studies have demonstrated that tubular involve-
ment may precede glomerular involvement, leading to an 
increase of various serum and urinary markers, including 
glomerular-transferrin,  fibronectin,  beta-2  microglobulin 
(β2M),  retinol  binding  protein,  alpha-1  microglobulin, 
ephrin-B2, annexin A7, paternally expressed 10 (PEG10), 
cystatin  C,  tamm-horsfall  protein,  beta  2  glycoprotein-1, 
urinary enzymes (N-acetyl-beta-D-glucosaminidase, choline-
sterase,  gamma  glutamyltranspeptidase,  alanine  amino-
peptidase),  and  tubular  brush-border  antigen,  following 
diabetic nephropathy.3-7  
Beta-2 microglobulin is a low molecular weight protein 
(11600 Da) found on the surface of lymphocytes and other 
nucleated cells. Free molecules are also detectable in the 
plasma  as  products  of  cell  turn  over,  particularly  from 
lymphocytes.  The  serum  concentrations  of  β2M  closely 
depends  on  renal  function  because  the  kidneys  are  the 
main site of clearance. 
The  β2M  is  a  major  component  in  dialysis-related 
amyloidosis, a disabling disease affecting long-term dialysis 
patients. Several studies have used β2M as a biomarker in 
diabetic  patients,8-11  but  little  is  known  about  the 
advantages  of  using  β2M  over  other  commonly  used 
parameters, such as serum creatinine (Cr) and blood urine 
nitrogen (BUN) for detection of the kidney disease. 
This study was aimed to find interrelationship of β2M, 
BUN  and  Cr  in  streptozotocin  (STZ)  induced  diabetic 
animals as a model. 
 
Materials and Methods 
 
Experimental  design.  Twelve  New  Zealand  White 
rabbits (weighing 1.5-2.0 kg) were randomly assigned into 
two groups of six and housed in separate cages at 23 ˚C 
with 12-hour cycles of light and darkness. Food and water 
were provided ad libitum. The animals in treatment group 
were made diabetic by intraperitoneal (IP) injection of 65 
mg kg-1 STZ (Sigma-Aldrich Co., St. Louis, USA) dissolved in 
citrate buffer with pH 4.5. The control rabbits received the 
same volume of citrate buffer alone. The development of 
diabetic state was confirmed by demonstration of fasting 
blood glucose levels > 200 mg dL-1 24 hr after STZ injection. 
Blood sampling. Blood samples were collected from the 
ear marginal veins (3 mL, needle gauge 25) of the all animals 
 
 
  of both groups at 24 hr intervals for up to three days, and 
then every week up to 12 weeks. Sera were isolated from 
blood samples in tubes with no anticoagulant, after being 
clotted for 30 min, and centrifuged at 2000 g for 5 min.  
Measurement of serum glucose level. Serum glucose 
levels were measured by the glucose oxidase method (GOD- 
PAP) using a glucose analysis kit (Randox Laboratories Ltd., 
Crumlin, UK) according to the manufacturer’s instructions. 
Measurement of serum insulin level. Serum insulin 
concentration  was  quantified  using  a  Human  Insulin 
ELISA  kit  (Millipore,  St.  Charles,  USA),  according  to  the 
manufacturer’s instructions.  
Measurement  of  serum  β2M  concentrations.  The 
β2M concentrations of the serum samples were determined 
using  a  β2M  ELISA  Kit  (Alpco diagnostics,  Salem,  USA), 
according  to  the  manufacturer’s  instructions,  with  few 
modifications.  Briefly,  100  µL  of  diluted  serum  (1:10 
dilution,  Sample  Diluent  including  2%  bovine  serum 
albumin  in  buffered  solution  containing  preservative) 
were loaded in duplicate wells in a 96-well plate coated 
with anti-human β2M monoclonal antibody and incubated 
at 37 ˚C for 30 min. The wells were washed five times with 
wash  buffer,  and  200  µL  of  horseradish  peroxidase-
conjugated  sheep  monoclonal  anti-β2M  antibody  were 
added into each well. The plate was further incubated at 
37 ˚C for 30 min. After five washes with buffer, 200 µL of 
substrate  solution  (3,3′,5,5′-Tetramethylbenzidine,  TMB) 
were  added  into  the  wells.  After  a  20  min  incubation 
period in a dark room, the reaction was stopped by adding 
100  µL  of  stop  solution  (0.5  M  sulfuric  acid),  and  the 
optical  density (OD)  of  yellow  color  developed  was 
determined within 15 min at 450 nm by using an ELISA 
plate reader (Denley Instruments Ltd., West Sussex, UK). A 
reference β2M standard, ranging from 0 to10 µg mL-1, was 
run in parallel with each experiment. 
Measurement of serum BUN and Cr levels. Serum 
BUN concentration was determined using a commercial kit 
(Pars Azmoon Co., Tehran, Iran), according to manufacturer’s 
instructions. Serum Cr was measured by Jaffe’s method, 
using a Commercial Kit (Pars Azmoon Co., Tehran, Iran).12 
Statistical analysis. Descriptive statistics were made 
using SPSS software, (Version 15; SPSS Inc., Chicago, USA). 
Two-way ANOVA  repeated  measurements  were used  to 
evaluate significant changes between healthy and diabetic 
groups, and during different days of study respective prior 
time  point  in  each  group.  Bonferroni  post  hoc  test  was 
used as a correction for multiple comparison. A p-value 
less than 0.05 was considered as significant. The data are 
presented as mean ± SD.  
 
Results  
 
Blood glucose concentrations increased 24 hr after STZ 
administrations and remained high during the course of the 
Study (Fig. 1).  Meanwhile, serum insulin concentrations   9  S. Javadi et al. Veterinary Research Forum. 2014; 5 (1) 7 - 11 
 
decreased  significantly  at  day  one,  and  reached  their 
minimum levels 11 weeks after STZ administration (Fig. 2). 
The BUN concentration in  healthy  and  diabetic  groups 
before injection was 25.00 ± 1.87 mg dL-1 and 24.60 ± 3.20 
mg dL-1, respectively. Except for weeks three and four with 
a remarkable decrease in BUN, its concentration showed 
an upward trend of increasing reaching 62.00 ± 4.60 mg dL-1 
at week 12 in the diabetic group (Fig. 3).  
 
 
 
 
 
 
 
 
 
 
 
 
Fig.  1.  Serum  glucose  concentrations  at  different  time  points. 
Significant differences between healthy and diabetic groups were 
observed in all time points after STZ administration. The serum 
glucose level in diabetic group on day 1 was significantly higher 
than before injection of STZ. 
 
 
 
 
 
 
 
 
 
 
 
 
Fig. 2.  Serum  Insulin  concentrations  at different  time  points. 
Apart from before injection and day 1, significant differences were 
observed between healthy and diabetic groups in other time points. 
 
 
 
 
 
 
 
 
 
 
 
 
Fig. 3. BUN levels at different time points. Significant difference 
between healthy and diabetic in each time point was started from 
day 2 onwards. Significant difference in the levels of BUN were 
observed on day two after STZ administration. 
  In diabetic rabbits, a steady increase also observed for 
the  Cr  concentrations  with  increase  Cr  over  time  in  the 
serum reaching its highest level of 4.34 ± 0.77 mg dL-1 at 
week 12 and a noticeable decrease at week three (Fig. 4). 
At  day  one,  the  serum level of  β2M  in  diabetic  group 
significantly  increased  (0.47 ±  0.19 µg  mL-1)  compared 
with its level before STZ administration (0.18 ± 0.03 µg mL-1), 
(p < 0.05). A significant difference was observed between 
the serum levels of β2M of diabetic group and those of the 
control ones (0.26 ± 0.04 µg mL-1), (p < 0.05) at day one 
post-STZ administration. The serum level of β2M reached 
3.54  ±  0.78  µg  mL-1  at  day  two  in  diabetic  group  and 
remained high for next nine weeks when at weeks 10 and 
11 it showed even a further increase of 7.08 ± 0.75 µg mL-1, 
and  7.16  ±  0.97  µg  mL-1,  respectively  whereas  in  the 
control  rabbits,  the  level  of  β2M  remained  low  with  no 
significant changes (Fig. 5). 
 
 
 
 
 
 
 
 
 
 
 
 
Fig. 4.  Serum  Cr  levels  at different  time  points.  Significant 
difference between healthy and diabetic in each time point was 
started from day 2 onwards. Significant difference in the levels of 
Cr were observed on day two after STZ administration. 
 
 
 
 
 
 
 
 
 
 
 
 
Fig. 5.  Serum  β2M  levels  at different  time  points.  Significant 
difference between healthy and diabetic in each time point was 
started from day 1 onwards. Significant difference in the levels of 
β2M were observed on day 1 after STZ administration. 
 
Discussion 
 
The  normal  ranges  of  glucose  and  insulin  in  healthy 
rabbits  were  determined  in  the  current  study.  In  the 
treatment group, serum glucose level gradually increased 
following administration of SZT to its peak on week 12, this 
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was  associated  with  a  gradual  decrease  in  secretion  of 
insulin,  which  reached  its  lowest  level  around  week  11 
after SZT injection. Significant reduction of serum insulin 
from day one to a minimal level of (0.12 ± 0.03 U μL-1) at 
week  eleven  after  STZ  administrations  indicated  the 
development of diabetes mellitus in rabbits of this study. 
Streptozotocin is widely used as a diabetogenic agent in 
animal models to induce diabetic nephropathy. However, it 
could  also  be  directly  cytotoxic  to  kidneys  making  it 
difficult  to  distinguish  between  diabetic-related  nephro-
pathy and STZ-induced nephropathy.12 One study reported 
that the STZ-induced diabetic rat was not suitable for long-
term studies because of progressive renal tumorigenesis.13 
Additionally,  weight  loss,  respiratory  distress,  rapid 
glycemic shifts resulting in life-threatening hypoglycemia, 
and a generalized poor body condition have already been 
described  as  adverse  effects  of  STZ  injection.14  Nephro-
toxicity  in  the  form  of  transient  proteinuria,  azotemia, 
abnormalities of tubular function, and acute renal failure, 
was  described  as  the  major  toxic  condition  following 
administration  of  STZ  and  it  has  been  suggested  that 
squamous  metaplasia  might  be  an  important  part  of 
streptozotocin renal toxicity.15 However, Evan et al. reported 
that,  in  contrast  with  alloxan,  streptozotocin  caused  no 
detectable renal injury at the dose 60 mg kg-1 which was 
approximately  as  the  one  we  used.  There  was  another 
study stating that no protection procedure was necessary 
for the kidney when STZ used for inducing  diabetes.16 
In the current study, the serum concentrations of Cr, 
and  BUN  were  determined  as  routine  tests  for  kidney 
function. The BUN concentration except for weeks three 
and four with a remarkable decrease showed an upward 
trend of increasing in the diabetic group. The concerned 
decrease can be explained by an insufficient progress in 
the regenerative process in the kidney. 
In diabetic rabbits, an almost similar pattern to BUN 
was also observed for the Cr concentrations with a steady 
increase in Cr over time in the serum reaching its highest 
level at week 12 and a noticeable decrease at week three. 
Increased  serum  levels  of  BUN,  Cr  and  β2M  in  diabetic 
rabbits could be caused by either kidney or none-kidney 
related factors. In rabbits prerenal azotemia can occur in 
association  with  stress,  water  deprivation,  severe 
dehydration, heat stroke and toxic insults. The rabbit has a 
limited capacity to concentrate urea and a greater volume 
of  urine  is  required  when  urea  load  increases.  It  is 
suggested that urea and Cr levels should be checked on a 
second  sample  before  making  an  absolute  diagnosis  of 
renal  failure  in  rabbits.17  As  no  histopathological 
examinations have been performed in the present study, 
thus it is difficult to associate the elevation of BUN and Cr 
to a  diabetic  nephropathy.  However, it has  been shown 
that high blood concentrations of urea and Cr in rabbits are 
usually associated with renal disease and antibody response 
to some infections.18 In clinical diabetic nephropathies, tests 
 
  for  Cr  and  BUN  are  routines  to  confirm  the  kidney’s 
involvement and to assess the associated pathology.19  
Measurements  of  the  levels  of  β2M  in  the  serum  of 
diabetic rabbits revealed a different pattern to BUN and Cr 
concentrations. From the second day of STZ injection, the 
β2M level rose rapidly, up to 6 times, compared to day 1, 
and increased steadily until week 2. From this time point, 
it fluctuated slightly until week 3 and then continued to 
rise to its peak at weeks 10 and 11.  
The β2M has been used as a biomarker for nephro-
pathies.20-23  However,  β2M  has  not  been  used  as  a 
common tool in assessment of diabetic renal involvement. 
Increased concentrations of β2M have been  reported in 
different studies due to viral infections including human 
immunodeficiency  virus  infection,  malignancies,  and  in 
autoimmune disorders. Increase of β2M in urine at early 
stage  of  cadmium  exposure  has  been  demonstrated.24 
Tsuchiya et al. showed that β2M in urine is very closely 
correlated  with  againg.25  Hyperthyroidism  is  another 
stimulant  of  β2M  production.26  In  our  study  significant 
increase  in  β2M,  Cr  and  BUN  in  diabetic  rabbits  were 
observed.  The  results  of  our  study  are  indicating  the 
earlier  at  increase  of  β2M  to  those  of  Cr  and  BUN 
suggesting a potential role for β2M as a biomarker in the 
assessment of possible kidney involvement in diabetes. It 
seems that  irrespective  of  the  root-causes  behind  rising 
level  of  Cr  and  BUN,  β2M  is  almost  always  increasing 
earlier to that of them in diabetic rabbits. 
Further  studies  in  animal  models  are  required  to 
determine  whether  urinary  β2M  can  be  considered  a 
valuable  diagnostic  biomarker  in  predicting  the 
development of kidney complications in diabetes.  
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